Short interest in shares of Greenwich LifeSciences, Inc. (GLSI Stock) (GLSI:NSD) decreased significantly during the month of December. As of the 15th of December, short interest totaled 194,300 shares, a 17.8% decrease from the 30th of November’s total of 236,400 shares.
Currently, the days-to-cover ratio is 5 days, based on an average daily trading volume of 39,000 shares. Currently, 5.4% of the company’s shares are sold short.
GLSI Stock-Insider Transactions:
Greenwich LifeSciences’s CEO Snehal Patel acquired 2,000 shares of the company’s stock on Friday, December 9th. GLSI stock was purchased at an average price per share of $13.11, for a total transaction value of $26,220.00.
As a result of the acquisition, the chief executive officer now owns 2,724,886 shares of the business worth $35,723,255.46.
During the most recent quarter, insiders purchased 13,500 shares of GLSI stock for $145,510.
14% of the shares are held by insiders.
Institutional Investors Holdings:
Several significant investors have recently adjusted their GLSI stock holdings.
Pura Vida Investments LLC acquired approximately $179,000 worth of shares of Greenwich LifeSciences during the third quarter.
Walleye Capital LLC purchased a new stake in Greenwich LifeSciences worth $90,000 during the second quarter.
During the second quarter, Goldman Sachs Group Inc. acquired a new position in Greenwich LifeSciences worth $104,000.
During the second quarter, Occudo Quantitative Strategies LP acquired a $199,000 position in Greenwich LifeSciences.
During the second quarter, Cubist Systematic Strategies LLC purchased a $130,000 position in Greenwich LifeSciences.
Institutional investors and hedge funds hold 6.18% of the GLSI stock.
Price Performance GLSI Stock:
Friday’s trading on the GLSI:NSD was down $0.07, reaching $15.20. Compared to its usual volume of 39,987 shares, the stock’s trading volume was 52,065 shares.
The 12-month low for Greenwich LifeSciences is $6.82 and the 12-month high is $26.27. The 50-day moving average price of the company is $12.07, while the 200-day moving average price is $10.20.
The company’s shares have a market capitalization of $194.86 million, a P/E ratio of -26.67, and a beta of 0.81.
Quarterly Earnings Overview:
On November 14th, Greenwich LifeSciences (GLSI:NSD) issued its most recent quarterly earnings report. The company reported quarterly earnings per share of ($0.18), beating the consensus estimate of ($0.19) by $0.01.
Sell-side analysts estimate, on average, that Greenwich LifeSciences will report a loss of $0.57 per share for the current fiscal year.
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers.
Its lead product candidate is the GP2, immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.